Compare AbCellera Biologics Inc (ABCL) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Oxford Lane Capital Corp — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while Oxford Lane Capital Corp trades at $9.05 (market cap $872.99M). The key difference: AbCellera Biologics Inc is far larger — about 2.7× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 26.85% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | OXLC | |
|---|---|---|
Market Cap | $2.35B | $872.99M |
Sector | Health | Financials |
52-Week High | $8.12 | $20.80 |
52-Week Low | $2.78 | $8.15 |
Enterprise Value | $1.99B | — |
Dividend Yield | — | 26.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
OXLC trades at $8.95, up 1.59% today, with a bullish technical signal but mixed indicators. The stock shows a P/B of 0.85, suggesting potential undervaluation, but profitability metrics are weak with a -39.16% ROE. Recent earnings have consistently missed expectations, including a significant Q1 2026 EPS miss. The company maintains a regular dividend payout of $0.20 per share, supporting income-focused investors despite fundamental challenges.
Outlook remains cautious due to persistent earnings underperformance and negative ROE/ROA. High dividend yield attracts income seekers, but sustainability concerns and NAV declines pose risks. Analyst consensus is divided, with 50% buy ratings balanced by bearish sentiment from financial media. Key risks include further NAV erosion and reliance on financing cash flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
